STAT+: Neurocrine Biosciences drug for congenital adrenal hyperplasia succeeds in late-stage trial
by Jonathan Wosen
Sep 12, 2023
1 minute
SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the
You’re reading a preview, subscribe to read more.
Start your free 30 days